Skip to main content
Erschienen in: Die Gastroenterologie 3/2021

19.03.2021 | Zytostatische Therapie | CME

Aktuelle lokale und systemische Therapie biliärer Tumoren

verfasst von: Prof. Dr. Arndt Vogel, Kai Timrott, Torsten Voigtländer, Anna Saborowski

Erschienen in: Die Gastroenterologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Biliäre Tumoren sind eine seltene Tumorentität. Aufgrund des oft lange klinisch inapparenten Verlaufs ist zum Zeitpunkt der Diagnose häufig bereits eine chirurgische Resektion nicht mehr möglich, sodass systemische und supportive Therapiekonzepte im Vordergrund stehen. Seit 2010 gilt die Chemotherapie mit Gemcitabin und Cisplatin als Standard in der palliativen Situation. Nach nahezu einer Dekade der Stagnation kommt aktuell Bewegung in die Systemtherapie biliärer Tumoren. Abgesehen von klassischen Chemotherapiekombinationen rücken dabei molekular zielgerichtete Konzepte in selektionierten Patientenkollektiven in den Vordergrund; insbesondere IDH1-Mutationen und FGFR2-Fusionen bei Patienten mit intrahepatischen Tumoren stehen dabei im Fokus der Untersuchungen. In diesem Artikel geben wir eine Übersicht über das chirurgische Vorgehen sowie lokale und systemische Therapiekonzepte in der adjuvanten und palliativen Therapie.
Literatur
1.
Zurück zum Zitat Valle JW, Bai L‑Y, Orlova R et al (2020) Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. J Clin Oncol 38:477–477CrossRef Valle JW, Bai L‑Y, Orlova R et al (2020) Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. J Clin Oncol 38:477–477CrossRef
2.
Zurück zum Zitat Valle JW, Furuse J, Jitlal M et al (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 25:391–398CrossRef Valle JW, Furuse J, Jitlal M et al (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 25:391–398CrossRef
3.
Zurück zum Zitat Farges O, Regimbeau JM, Fuks D et al (2013) Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 100:274–283CrossRef Farges O, Regimbeau JM, Fuks D et al (2013) Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 100:274–283CrossRef
4.
Zurück zum Zitat Mehrabi A, Khajeh E, Ghamarnejad O et al (2020) Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma. Eur J Radiol 125:108897CrossRef Mehrabi A, Khajeh E, Ghamarnejad O et al (2020) Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma. Eur J Radiol 125:108897CrossRef
5.
Zurück zum Zitat Iacono C, Ruzzenente A, Campagnaro T et al (2013) Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg 257:191–204CrossRef Iacono C, Ruzzenente A, Campagnaro T et al (2013) Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg 257:191–204CrossRef
6.
Zurück zum Zitat Coelen RJS, Roos E, Wiggers JK et al (2018) Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 3:681–690CrossRef Coelen RJS, Roos E, Wiggers JK et al (2018) Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 3:681–690CrossRef
7.
Zurück zum Zitat Voigtlander T, Schweitzer N, Von Hahn T et al (2019) Endoscopic biliary drainage in patients with cholangiocarcinoma—self-expanding metal versus polyethylene stents. Scand J Gastroenterol 54:640–645CrossRef Voigtlander T, Schweitzer N, Von Hahn T et al (2019) Endoscopic biliary drainage in patients with cholangiocarcinoma—self-expanding metal versus polyethylene stents. Scand J Gastroenterol 54:640–645CrossRef
8.
Zurück zum Zitat Park JK, Woo YS, Noh DH et al (2018) Efficacy of EUS-guided and ERCP-guided biliary drainage for malignant biliary obstruction: prospective randomized controlled study. Gastrointest Endosc 88:277–282CrossRef Park JK, Woo YS, Noh DH et al (2018) Efficacy of EUS-guided and ERCP-guided biliary drainage for malignant biliary obstruction: prospective randomized controlled study. Gastrointest Endosc 88:277–282CrossRef
9.
Zurück zum Zitat Paik WH, Lee TH, Park DH et al (2018) EUS-guided biliary drainage versus ERCP for the primary palliation of malignant Biliary obstruction: a multicenter randomized clinical trial. Am J Gastroenterol 113:987–997CrossRef Paik WH, Lee TH, Park DH et al (2018) EUS-guided biliary drainage versus ERCP for the primary palliation of malignant Biliary obstruction: a multicenter randomized clinical trial. Am J Gastroenterol 113:987–997CrossRef
10.
Zurück zum Zitat Leggett CL, Gorospe EC, Murad MH et al (2012) Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn Ther 9:189–195CrossRef Leggett CL, Gorospe EC, Murad MH et al (2012) Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn Ther 9:189–195CrossRef
11.
Zurück zum Zitat Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673CrossRef Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673CrossRef
13.
Zurück zum Zitat Bargellini I, Mosconi C, Pizzi G et al (2020) Yttrium-90 radioembolization in unresectable Intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol 43:1305–1314CrossRef Bargellini I, Mosconi C, Pizzi G et al (2020) Yttrium-90 radioembolization in unresectable Intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol 43:1305–1314CrossRef
14.
Zurück zum Zitat Brinkhaus G, Lock JF, Malinowski M et al (2014) CT-guided high-dose-rate brachytherapy of liver tumours does not impair hepatic function and shows high overall safety and favourable survival rates. Ann Surg Oncol 21:4284–4292CrossRef Brinkhaus G, Lock JF, Malinowski M et al (2014) CT-guided high-dose-rate brachytherapy of liver tumours does not impair hepatic function and shows high overall safety and favourable survival rates. Ann Surg Oncol 21:4284–4292CrossRef
15.
Zurück zum Zitat Marquardt S, Kirstein MM, Bruning R et al (2018) Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 29(4):1882–1892. https://doi.org/10.1007/s00330-018-5729-z Marquardt S, Kirstein MM, Bruning R et al (2018) Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 29(4):1882–1892. https://​doi.​org/​10.​1007/​s00330-018-5729-z
16.
Zurück zum Zitat Garin E, Tselikas L, Guiu B et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6:17–29CrossRef Garin E, Tselikas L, Guiu B et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6:17–29CrossRef
17.
Zurück zum Zitat Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRef Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281CrossRef
18.
Zurück zum Zitat Kim ST, Kang JH, Lee J et al (2019) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 30:788–795CrossRef Kim ST, Kang JH, Lee J et al (2019) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 30:788–795CrossRef
19.
Zurück zum Zitat Shroff RT, Javle MM, Xiao L et al (2019) Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol 5:824–830CrossRef Shroff RT, Javle MM, Xiao L et al (2019) Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol 5:824–830CrossRef
20.
Zurück zum Zitat Phelip JM, Desrame J, Edeline J et al (2020) Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: results of AMEBICA PRODIGE 38 randomized phase II trial. Ann Oncol 31:S260–S261CrossRef Phelip JM, Desrame J, Edeline J et al (2020) Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: results of AMEBICA PRODIGE 38 randomized phase II trial. Ann Oncol 31:S260–S261CrossRef
21.
Zurück zum Zitat Lamarca A, Ross P, Wasan HS et al (2020) Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst 112:200–210PubMed Lamarca A, Ross P, Wasan HS et al (2020) Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst 112:200–210PubMed
22.
Zurück zum Zitat Lamarca A, Hubner RA, David Ryder W et al (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25:2328–2338CrossRef Lamarca A, Hubner RA, David Ryder W et al (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25:2328–2338CrossRef
23.
Zurück zum Zitat Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116–1135CrossRef Jusakul A, Cutcutache I, Yong CH et al (2017) Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 7:1116–1135CrossRef
24.
Zurück zum Zitat Javle MM, Murugesan K, Shroff RT et al (2019) Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). J Clin Oncol 37:4087–4087CrossRef Javle MM, Murugesan K, Shroff RT et al (2019) Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). J Clin Oncol 37:4087–4087CrossRef
25.
Zurück zum Zitat Silverman IM, Murugesan K, Lihou CF et al (2019) Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma. J Clin Oncol 37:4080–4080CrossRef Silverman IM, Murugesan K, Lihou CF et al (2019) Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma. J Clin Oncol 37:4080–4080CrossRef
26.
Zurück zum Zitat Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796–807CrossRef Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796–807CrossRef
28.
Zurück zum Zitat Javle MM, Hainsworth JD, Swanton C et al (2017) Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from Mypathway. J Clin Oncol 35:402–402CrossRef Javle MM, Hainsworth JD, Swanton C et al (2017) Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from Mypathway. J Clin Oncol 35:402–402CrossRef
29.
Zurück zum Zitat Hainsworth JD, Meric-Bernstam F, Swanton C et al (2018) Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol 36:536–542CrossRef Hainsworth JD, Meric-Bernstam F, Swanton C et al (2018) Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol 36:536–542CrossRef
31.
Zurück zum Zitat Marabelle A, Le DT, Ascierto PA et al. (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1–10. https://doi.org/10.1200/JCO.19.02105 Marabelle A, Le DT, Ascierto PA et al. (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1–10. https://​doi.​org/​10.​1200/​JCO.​19.​02105
Metadaten
Titel
Aktuelle lokale und systemische Therapie biliärer Tumoren
verfasst von
Prof. Dr. Arndt Vogel
Kai Timrott
Torsten Voigtländer
Anna Saborowski
Publikationsdatum
19.03.2021
Verlag
Springer Medizin
Erschienen in
Die Gastroenterologie / Ausgabe 3/2021
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-021-00514-6

Weitere Artikel der Ausgabe 3/2021

Die Gastroenterologie 3/2021 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI